Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02836925 |
Recruitment Status :
Active, not recruiting
First Posted : July 19, 2016
Last Update Posted : December 28, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Indolent B-cell Lymphoma Hepatitis C | Drug: Ledipasvir+Sofosbuvir Drug: Sofosbuvir+Velpatasvir | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 40 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Multicenter Study to Evaluate the Anti-viral Activity of an Interferon-free Treatment With Ledipasvir/Sofosbuvir (G1 and G4) and Sofosbuvir/Velpatasvir (G2 and G3) for Patients With Hepatitis C Virus-associated Indolent B-cell Lymphomas |
Study Start Date : | March 2016 |
Actual Primary Completion Date : | February 2020 |
Estimated Study Completion Date : | May 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: Ledipasvir+Sofosbuvir,Sofosbuvir+Velpatasvir
The study includes an antiviral treatment with interferon-free regimen followed by lymphoma restaging; following the end of antiviral treatment patients will be evaluated for sustained virological response and safety parameters every 3 months for 1 year and then every 6 months for 2 years. ORR and vital status will be also evaluated
|
Drug: Ledipasvir+Sofosbuvir
Patients with genotype 1 or genotype 4 Ledipasvir 90 mg + Sofosbuvir 400 mg
Other Name: Harvoni Drug: Sofosbuvir+Velpatasvir Patients with genotype 2 or genotype 3 Sofosbuvir 400 mg + Velpatasvir 100 mg · 12 weeks of treatment Other Name: Epclusa |
- SVR12 [ Time Frame: 12 weeks from the end of the treatment ]Sustained virologic response (SVR12) defined as undetectability of HCV-RNA 12 weeks after completion of antiviral therapy
- ORR [ Time Frame: 12 weeks from the end of treatment ]Overall response rate (ORR) of lymphoma: CR is defined by the complete disappearance of all detectable sites and symptoms; PR is defined as a more than 50% reduction. Responses different from CR/PR are defined as stable disease (SD); progressive disease (PD) is considered an increase in size of more than 50% of previously documented disease or the appearance of new lesions. Lymphoma response will be assessed 12 weeks after the end of antiviral treatment
- PFS [ Time Frame: 36 months ]Progression-free survival (PFS) defined as the time between enrolment and progression or relapse or death from any cause.
- EFS [ Time Frame: 36 months ]Event-free survival (EFS) defined as time between enrolment and failure of treatment or death as a result of any cause
- OS [ Time Frame: 36 months ]Overall survival (OS) defined as the time between enrolment and death from any cause
- ORR for lymphoma [ Time Frame: 12 weeks from the end of treatment ]ORR for lymphoma according to Matutes criteria (Matutes et al, Leukemia 2008) only in patients with splenic-marginal zone lymphoma (SMZL)
- Rapid virological response [ Time Frame: 4 weeks ]rapid virologic response (RVR)
- Extended rapid virological response [ Time Frame: 4 weeks ]extended RVR (eRVR)
- Early virological response [ Time Frame: 4 weeks ]early virologic response (EVR)
- Toxicity - Incidence of Adverse Events [ Time Frame: 12 months ]toxicity will be classified according to definitions of Common Terminology Criteria for Adverse Event version 4.03 (CTCAE). It will be determined by the incidence of severe, life-threatening (CTCAE grade 3, 4 and 5) and/or serious adverse events

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age >18 years
- Indolent B cell lymphoma including: marginal zone lymphoma (nodal, extranodal, splenic and disseminated), lymphoplasmacytic lymphoma, small lymphocytic lymphoma, follicular lymphoma grade 1 and 2, CD5-negative B-cell lymphoma NOS
- HCV-RNA positivity
- Assessable HCV genotype
- No previous therapy for the lymphoma
- Measurable disease after diagnostic biopsy (longest axis ≥1.5 cm for nodal and ≥1 cm for extranodal lesions) and/or evaluable disease (quantifiable BM infiltrate and ≥5 x 109/l clonal B-cell in peripheral blood in case of exclusive BM/leukemic disease in CD5-negative Bcell lymphoma NOS)
- No need of immediate lymphoma treatment defined as absence of all the following criteria: systemic symptoms, bulky nodal or extranodal mass (>7 cm), symptomatic splenomegaly, progressive leukemic phase, serous effusions
- Performance status <2 according to ECOG scale
- Adequate hematological counts: ANC >1 x 109/L, hemoglobin >9 g/dl (transfusion independent), platelet count > 50 x 109/L (transfusion independent)
- No central nervous system (CNS) disease (meningeal and/or brain involvement by lymphoma)
- Adequate kidney function (creatinine clearance ≥ 45 ml/min)
- Cardiac ejection fraction ≥45% (echocardiography or MUGA scan)
- Normal lung function
- Non peripheral neuropathy or active neurological non neoplastic disease of CNS
- Non major surgical intervention prior 3 months to enrolment if not due to lymphoma and/or no other disease life-threatening that can compromise chemotherapy treatment
- Disease free of prior malignancies other than lymphoma for >3 years with exception of currently treated squamous cell and basal cell carcinoma of the skin or carcinoma in situ of the cervix or breast
- Life expectancy > 6 months
- No psychiatric illness that precludes understanding concepts of the trial or signing informed consent
- Written informed consent
-
Women must be:
- postmenopausal for at least 1 year (must not have had a natural menses for at least 12 months)
- surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy),
- completely abstinent (at the discretion of the investigator/per local regulations) (periodic abstinence from intercourse is not permitted) or
- if sexually active, be practicing a highly effective method of birth control (eg, prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method (eg: condoms, diaphragm, or cervical cap, with spermicidal foam, cream, or gel, male partner sterilization) as local regulations permit, before entry, and must agree to continue to use the same method of contraception throughout the study. They must also be prepared to continue birth control measures for at least 6 months after terminating treatment.
- Women of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening
- Men must agree to use an acceptable method of contraception (for themselves or female partners as listed above) for the duration of the study. Men must agree to use a double barrier method of birth control and to not donate sperm during the study and for 1 month after receiving the last dose of study drug if not taking ribavirin of for 6 months after receiving the last dose of study drug if taking ribavirin.
Exclusion Criteria:
- Diagnosis of lymphoblastic lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma grade 3, primary mediastinal B-cell lymphoma
- Previous anti-HCV treatment with sustained virological response
- Diagnosis of cirrhosis (histological or Stiffness >12 KpA)
- CNS disease (meningeal and/or brain involvement by lymphoma)
- History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances
- Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months before first dose of study drug)
- Concomitant therapy with amiodarone
- Uncontrolled or severe cardiovascular disease including myocardial infarction within six months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina,
- Cardiac ejection fraction <45% (MUGA scan or echocardiography).
- Creatinine clearance <45 ml/min
- Presence of major neurological disorders
- HIV positivity, HBV positivity (HbsAg+ or HBV-DNA+) with the exception of HBcAb+, HbsAg-, HBsAb+/- patients with HBV-DNA negativity
- Ongoing systemic bacterial, fungal or viral infections at the time of initiation of study treatment (defined as requiring therapeutic dosing of an antimicrobial, antifungal or antiviral agent)
- Major surgical intervention prior 3 months to enrollment if not due to lymphoma and/or other
- Prior malignancies other than lymphoma in the last 3 years with exception of currently treated squamous cell and basal cell carcinoma of the skin or carcinoma in situ of the cervix or breast
- Life expectancy <6 months
- Any other coexisting medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent.
- If female, the patient is pregnant or breast-feeding.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02836925

Principal Investigator: | Luca Arcaini | Policlinico San Matteo Pavia Fondazione IRCCS |
Responsible Party: | Fondazione Italiana Linfomi ONLUS |
ClinicalTrials.gov Identifier: | NCT02836925 |
Other Study ID Numbers: |
FIL_BArT |
First Posted: | July 19, 2016 Key Record Dates |
Last Update Posted: | December 28, 2020 |
Last Verified: | December 2020 |
hepatitis C NHL Indolent B-cell lymphoma |
Hepatitis A Hepatitis C Lymphoma Lymphoma, B-Cell Hepatitis Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Liver Diseases Digestive System Diseases |
Hepatitis, Viral, Human Virus Diseases Enterovirus Infections Picornaviridae Infections RNA Virus Infections Flaviviridae Infections Lymphoma, Non-Hodgkin Sofosbuvir Ledipasvir, sofosbuvir drug combination Ledipasvir Velpatasvir Antiviral Agents Anti-Infective Agents |